A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia

Gibson, Clare M.; Penn, David L.; Smedley, Kelly L.; Leserman, Jane; Elliott, Tonya; Pedersen, Cort A.

doi:10.1016/j.schres.2014.04.009

Cited by 81 publications

(87 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A positive correlation between SZ progression and oxytocin levels in the central nervous system has been observed [Beckmann et al, 1985], and it is plausibly explained by a decreased sensitivity to the hormone [Glovinsky et al, 1994;Sasayama et al, 2012;Strauss et al, 2015]. Treatment with oxytocin indeed improves the performance of verbal memory learning tasks in SZ patients [Feifel et al, 2012], and attenuates the negative symptoms of the disease [Feifel et al, 2010;Modabbernia et al, 2013;Davis et al, 2014;Gibson et al, 2014].…”

Section: Behavioral Traits and Neuroendocrine Impairmentmentioning

confidence: 95%

Schizophrenia and Human Self-Domestication: An Evolutionary Linguistics Approach

et al. 2017

View full text Add to dashboard Cite

Schizophrenia (SZ) is a pervasive neurodevelopmental disorder that entails social and cognitive deficits, including marked language problems. Its complex multifactorial etiopathogenesis, including genetic and environmental factors, is still widely uncertain. SZ incidence has always been high and quite stable in human populations, across time and regardless of cultural implications, for unclear reasons. It has been hypothesized that SZ pathophysiology may involve the biological components that changed during the recent human evolutionary history, and led to our distinctive mode of cognition, which includes language skills. In this paper we explore this hypothesis, focusing on the self-domestication of the human species. This has been claimed to account for many human-specific distinctive traits, including aspects of our behavior and cognition, and to favor the emergence of complex languages through cultural evolution. The “domestication syndrome” in mammals comprises the constellation of traits exhibited by domesticated strains, seemingly resulting from the hypofunction of the neural crest. It is our intention to show that people with SZ exhibit more marked domesticated traits at the morphological, physiological, and behavioral levels. We also show that genes involved in domestication and neural crest development and function comprise nearly 20% of SZ candidates, most of which exhibit altered expression profiles in the brain of SZ patients, specifically in areas involved in language processing. Based on these observations, we conclude that SZ may represent an abnormal ontogenetic itinerary for the human faculty of language, resulting, at least in part, from changes in genes important for the domestication syndrome and primarily involving the neural crest.

show abstract

Section: Behavioral Traits and Neuroendocrine Impairmentmentioning

confidence: 95%

Schizophrenia and Human Self-Domestication: An Evolutionary Linguistics Approach

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The previous meta-analysis included four RCTs [8,20,27,31] that evaluated the psychopathology and found that total symptoms, positive symptoms, and negative symptoms improved significantly in the oxytocin group; however, the Positive and Negative Syndrome Scale (PANSS) [18] general subscale scores did not improve in comparison with the placebo group (Table 1). However, seven RCTs with oxytocin have been conducted for the treatment of schizophrenia to date [5,7,8,12,20,27,31]. Therefore, the sample size of the current study (n = 206) is now larger than that of the previous study (n = 105).…”

Section: Introductionmentioning

confidence: 91%

“…The primary study outcome for efficacy was improvement in total symptoms, and that for safety was all-cause discontinuation rate. Total symptoms were measured using the PANSS total scores [8,12,27,31] and the Brief Psychiatric Rating Scale (BPRS) [30] total scores [7,20]. Secondary efficacy outcomes were positive and negative symptom scores and the PANSS general subscale scores.…”

Section: Data Synthesis and Outcomesmentioning

confidence: 99%

“…Secondary efficacy outcomes were positive and negative symptom scores and the PANSS general subscale scores. Positive symptoms were measured using the PANSS positive subscale scores [8,12,27,31], the Scale for the Assessment of Positive Symptoms (SAPS) [2] total scores [5], and the BPRS positive subscale scores [20]. Negative symptoms were measured using the PANSS negative subscale scores [8,12,27,31], the Scale for the assessment of negative symptoms (SANS) [1] total scores [5,20], the clinical assessment interview for negative symptoms (CAINS) [11] total scores [7], and the PANSS general subscale scores [8,12,31].…”

Section: Data Synthesis and Outcomesmentioning

confidence: 99%

“…cochrane.org/). Considering this, we performed an updated meta-analysis of oxytocin augmentation therapy for the patients with schizophrenia using the data from the seven published RCTs [5,7,8,12,20,27,31]. It comprehensively evaluated the efficacy and safety of oxytocin in the management of schizophrenia (including the discontinuation rate and individual side effects).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials

Oya

Matsuda

Matsunaga

et al. 2015

Eur Arch Psychiatry Clin Neurosci

View full text Add to dashboard Cite

The aim of this study was to perform a systematic review and an updated and comprehensive meta-analysis of oxytocin augmentation therapy in patients with schizophrenia who received antipsychotic agents. Data published up to 07/11/2015 were obtained from PubMed, PsycINFO, and Cochrane Library databases. We conducted a systematic review and meta-analysis of patients' data from randomized controlled trials (RCTs) comparing oxytocin with placebo. Relative risk (RR), standardized mean difference (SMD), and 95 % confidence intervals (95 % CI) based on the random-effects model were calculated. We included seven RCTs; the total sample size was 206 patients. Oxytocin was superior to placebo for decreasing the Positive and Negative Syndrome Scale (PANSS) general subscale scores (SMD = -0.44, 95 % CI -0.82 to -0.06, p = 0.02, I (2) = 0 %, N = 4, n = 112); however, it was not different from placebo for total symptoms (SMD = -0.46, 95 % CI -1.20 to 0.28, p = 0.22, I (2) = 80 %, N = 6, n = 162), positive symptoms (SMD = -0.18, 95 % CI -0.87 to 0.51, p = 0.60, I (2) = 81 %, N = 6, n = 192), and negative symptoms (SMD = -0.34, 95 % CI -0.76 to 0.08, p = 0.12, I (2) = 55 %, N = 7, n = 214). However, a sensitivity analysis including only oxytocin administration on consecutive days studies was superior to placebo in negative symptoms (SMD = -0.44, 95 % CI -0.87 to -0.01, p = 0.04, I (2) = 51 %, N = 6 n = 192). There were no significant differences for all-cause discontinuation (RR = 1.02) and individual side effects such as headache and dizziness between oxytocin and placebo. Oxytocin may improve PANSS general subscale scores in schizophrenia and seems to be well tolerated. However, because the number of studies in the current analysis was small, further study will be required using larger sample sizes.

show abstract

Role of Oxytocin in Different Neuropsychiatric, Neurodegenerative, and Neurodevelopmental Disorders

Ghazy

Soliman

Elbahnasi

et al. 2022

Reviews of Physiology, Biochemistry and Pharmacology

View full text Add to dashboard Cite

A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia

Cited by 81 publications

References 32 publications

Schizophrenia and Human Self-Domestication: An Evolutionary Linguistics Approach

Schizophrenia and Human Self-Domestication: An Evolutionary Linguistics Approach

Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials

Role of Oxytocin in Different Neuropsychiatric, Neurodegenerative, and Neurodevelopmental Disorders

Contact Info

Product

Resources

About